J Korean Neuropsychiatr Assoc.
2002 Jan;41(1):138-145.
A Validation Study of Korean-version of Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS): Liverpool University Neuroleptic Side Effect Rating Scale (LUNSERS)
- Affiliations
-
- 1Department of Psychiatry, Seoul National University College of Medicine, Boramae Hospital, Seoul, Korea.
- 2Department of Psychiatry, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
- 3Seoul Institute of Clinical Psychology, Seoul, Korea.
- 4Seoul National Mental Hospital, Seoul, Korea.
- 5Department of Psychiatry, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea.
Abstract
- OBJECTIVES: This study was conducted to develop the Korean version of Liverpool University Neuroleptic Side Effect Rating Scale(LUNSERS) for measuring neuroleptic side effects by self-rating method and to examine the reliability and validity in the schizophrenic patients medicated by neuroleptics and normal controls.
METHODS
We made 51-item, 4-point scale of Korean version LUNSERS through translation, reverse translation and supervision by specialists. Sixty two schizophrenics diagnosed by DSM-IV criteria and medicated with neuroleptics completed LUNSERS twice with one week interval. Second LUNSERS and UKU side effect rating scale (UKU) by psychiatrist were administered to the schizophrenics at the same time. Normal controls also completed LUNSERS.
RESULTS
The test-retest reliability (r=0.86, p<0.01) of LUNSERS and the concurrent validity (r=0.81, p<0.001) against UKU were good. But the neuroleptic doses and total scores of side effect items didn't show significant correlation. By the ROC curve analysis, the total scores of side effect items differentiated the medicated patients from non-medicated controls but not for the red herring items.
CONCLUSION
Korean-version of LUNSERS has good reliability and validity. And it was also proved to be an useful assessment tool for measuring the extent of neuroleptic side effects systematically instead of UKU in clinical trials.